



PERMANENT ADMINISTRATIVE ORDER

OBNM 2-2023

CHAPTER 850

OREGON BOARD OF NATUROPATHIC MEDICINE

FILED

06/23/2023 10:57 AM
ARCHIVES DIVISION
SECRETARY OF STATE
& LEGISLATIVE COUNSEL

FILING CAPTION: Removes formulary exclusion for Buprenorphine for diagnosis for opioid use disorder.

EFFECTIVE DATE: 06/23/2023

AGENCY APPROVED DATE: 06/12/2023

CONTACT: Mary-Beth Baptista
971-673-0193
naturopathic.medicine@obnm.oregon.gov

800 NE Oregon Street, Ste 407
Portland, OR 97232

Filed By:
Mary-Beth Baptista
Rules Coordinator

AMEND: 850-060-0223

REPEAL: Temporary 850-060-0223 from OBNM 1-2023

RULE TITLE: Formulary Compendium Exclusions

NOTICE FILED DATE: 03/08/2023

RULE SUMMARY: Removes formulary exclusion for Buprenorphine for diagnosis for opioid use disorder.

RULE TEXT:

The Formulary Council has approved substances as listed by classification in 850-060-0226 for use by Naturopathic physicians in accordance with professional standards of care.

(1) This authority does not supersede the education and training requirement established in 850-060-0212 for administration of IV agents or any other education and training required to prescribe, dispense, administer, or order all legend or controlled substances.

(2) Additionally, the following substances may not be prescribed by licensees of this Board.

(a) General anesthetics

(b) Injectable Ketamine for the purpose of general anesthesia

(c) Mifepristone and Misoprostol as an abortifacient

(d) Barbiturates; with the exception of the following:

(A) Phenobarbital

(B) Butalbital

(C) Primidone

(e) Systemic oncology agents with the exception of the following antineoplastic agents, in oral and topical form only.

(A) 5FU

(B) Anastrozole

(C) Letrozole

(D) Mechlorethamine

(E) Megestrol

(F) Mercaptopurine

(G) Methotrexate

(H) Tamoxifen

(I) Tretinoin

(f) Any other substance not listed in 850-060-0226 classification or meeting prior approval of the Board.

STATUTORY/OTHER AUTHORITY: ORS 685.125

STATUTES/OTHER IMPLEMENTED: ORS 685.030